Recombinant Human monoclonal antibody expressed in CHO binding to Human ACVRL1. PF-03446962, a fully-human monoclonal antibody against transforming growth-factor β (TGFβ) receptor ALK1, in pre-treated patients with urothelial cancer: an open label, single-group, phase 2 trial.
Figure 1 Anti-Human ACVRL1 Recombinant Antibody (TAB-013CL) in SDS-PAGE
Lane 1: Non-reducing (2.0 µg) Lane 2: Reducing (1.0 µg)
This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:
• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production
See more details about Hi-Affi™ recombinant antibody benefits.
Download resources about recombinant antibody development and antibody engineering to boost your research.
Select a product category from the dropdown menu below to view related products.
CAT | Product Name | Application | Type |
---|---|---|---|
MOR-0065 | Hi-Affi™ Rabbit Anti-ACVRL1 Recombinant Antibody (clone DS65AB) | ELISA | Rabbit IgG |
To accurately reference this product in your publication, please use the following citation information:
(Creative Biolabs Cat# TAB-013CL, RRID: AB_3111744)
For Research Use Only. Not For Clinical Use.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.